Showing results (21-30 of 82) with videos related to
Sort By:
Pageof 9
Molecular Microbiology|December 1, 2009
Three new RelE-homologous mRNA interferases of Escherichia coli differentially induced by environmental stressesMikkel Christensen-Dalsgaard, Mikkel Girke Jørgensen, Kenn GerdesExpert Opinion on Drug Metabolism & Toxicology|October 26, 2012
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerationsMaria J Jespersen, Filip K Knop, Mikkel ChristensenThe Cochrane Database of Systematic Reviews|January 23, 2023
Medication review in hospitalised patients to reduce morbidity and mortalityCille Bülow, Stine Søndersted Clausen, Andreas Lundh, et al.Expert Opinion on Investigational Drugs|March 12, 2011
Lixisenatide for type 2 diabetes mellitusMikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.Methods in Enzymology|January 24, 2009
RNA decay by messenger RNA interferasesMikkel Christensen-Dalsgaard, Martin Overgaard, Kristoffer Skovbo Winther, et al.The Review of Diabetic Studies : RDS|January 21, 2012
Therapy for obesity based on gastrointestinal hormonesJonatan I Bagger, Mikkel Christensen, Filip K Knop, et al.The Review of Diabetic Studies : RDS|January 21, 2012
The alpha-cell as target for type 2 diabetes therapyMikkel Christensen, Jonatan I Bagger, Tina Vilsbøll, et al.Expert Opinion on Drug Metabolism & Toxicology|July 14, 2015
Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacyAndreas Brønden, Signe V Naver, Filip K Knop, et al.Microbial Cell Factories|December 21, 2021
High natural PHA production from acetate in Cobetia sp. MC34 and Cobetia marina DSM 4741<sup>T</sup> and in silico analyses of the genus specific PhaC<sub>2</sub> polymerase variantMikkel Christensen, Piotr Jablonski, Bjørn Altermark, et al.Idrugs : the Investigational Drugs Journal|July 25, 2009
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitusMikkel Christensen, Filip K Knop, Jens J Holst, et al.Pageof 9